Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Multiple sclerosis: diagnostic procedures and current therapeutic developments]

L Kappos1

  • 1Neurologische Universitätsklinik, Kantonsspital Basel.

Schweizerische Medizinische Wochenschrift
|June 24, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.

Journal of neurology·2023
Same author

Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis.

AJNR. American journal of neuroradiology·2023
Same author

Prognostic biomarkers in primary progressive multiple sclerosis: Validating and scrutinizing multimodal evoked potentials.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2022
Same author

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2020
Same author

Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.

European journal of neurology·2020
Same author

Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods.

European radiology·2019
Same journal

Respiratory function test in the case of temporary phrenic nerve contusion, associated with pneumoperitoneum; About the diagnostic value of laparoscopy.

Schweizerische medizinische Wochenschrift·2010
Same journal

Treatment of pulmonary tuberculosis and pleurisy by means of temporary paralysis of the diaphragm, supported by the pneumoperitoneum.

Schweizerische medizinische Wochenschrift·2010
Same journal

Boeck's disease as a tuberculous syndrome.

Schweizerische medizinische Wochenschrift·2010
Same journal

Enteral primary tubercular complexes

Schweizerische medizinische Wochenschrift·2010
Same journal

Tuberculous stenoses of the large bronchi.

Schweizerische medizinische Wochenschrift·2010
Same journal

About the enzyme action.

Schweizerische medizinische Wochenschrift·2010
See all related articles

Diagnosing multiple sclerosis requires clinical evidence of CNS lesions and relapses or chronic progression. Emerging immunomodulatory treatments show promise for improving prognosis in relapsing-remitting MS.

Area of Science:

  • Neurology
  • Immunology

Context:

  • Multiple sclerosis (MS) diagnosis relies on clinical presentation and paraclinical findings.
  • No single symptom or test is pathognomonic for MS, necessitating comprehensive evaluation.

Purpose:

  • To outline the diagnostic criteria for multiple sclerosis.
  • To review current and emerging therapeutic strategies for MS.
  • To discuss future directions in MS diagnosis and treatment.

Summary:

  • MS diagnosis involves documenting lesions in at least two central nervous system (CNS) sites and either two relapses (relapsing-remitting MS) or 6 months of progressive deterioration (chronic-progressive MS).
  • Differential diagnosis is crucial, aided by cerebrospinal fluid (CSF) examination, blood serology, magnetic resonance imaging (MRI), and evoked potentials.

Related Experiment Videos

  • Current research indicates that immunomodulatory treatments, including interferon beta-1b, interferon beta-1a, and copolymer 1, alongside high-dose steroids for acute relapses, can improve outcomes in relapsing-remitting MS.
  • Non-selective immunosuppressants like azathioprine are used in select cases, with ongoing investigations into their efficacy for secondary chronic-progressive MS and the benefits of early intervention.

    • Impact:

    • Provides a concise overview of MS diagnostic standards and therapeutic advancements.
    • Highlights the evolving landscape of MS management, emphasizing early intervention and novel immunomodulatory agents.
    • Informs clinicians and researchers about the current state and future potential of multiple sclerosis care.